We investigated the mechanisms of anticoagulant activity mediated by sulfated galactans. The anticoagulant activity of sulfated polysaccharides is achieved mainly through potentiation of plasma cofactors, which are the natural inhibitors of coagulation proteases. Our results indicated the following. 1) Structural requirements for the interaction of sulfated galactans with coagulation inhibitors and their target proteases are not merely a consequence of their charge density. 2) The structural basis of this interaction is complex because it involves naturally heterogeneous polysaccharides but depends on the distribution of sulfate groups and on monosaccharide composition. 3) Sulfated galactans require significantly longer chains than heparin to achieve anticoagulant activity. 4) Possibly, it is the bulk structure of the sulfated galactan, and not a specific minor component as in heparin, that determines its interaction with antithrombin. 5) Sulfated galactans of ϳ15 to ϳ45 kDa bind to antithrombin but are unable to link the plasma inhibitor and thrombin. This last effect requires a molecular size above 45 kDa. 6) Sulfated galactan and heparin bind to different sites on antithrombin. 7) Sulfated galactans are less effective than heparin at promoting antithrombin conformational activation. Overall, these observations indicate that a different mechanism predominates over the conformational activation of antithrombin in ensuring the antithrombin-mediated anticoagulant activity of the sulfated galactans. Possibly, sulfated galactan connects antithrombin and thrombin, holding the protease in an inactive form. The conformational activation of antithrombin and the consequent formation of a covalent complex with thrombin appear to be less important for the anticoagulant activity of sulfated galactan than for heparin. Our results demonstrate that the paradigm of heparin-antithrombin interaction cannot be extended to other sulfated polysaccharides. Each type of polysaccharide may form a particular complex with the plasma inhibitor and the target protease.
The leading causes of death are now diseases that involve heart and blood vessels and as a consequence thrombosis (1) . This explains the current efforts to develop specific and potent antithrombotic agents. Most thromboembolic conditions require anticoagulant therapy; heparin has been used for more than 50 years. The potent anticoagulant action of heparin is achieved mainly through potentiation of antithrombin and heparin cofactor II, the major inhibitors of coagulation enzymes, in particular thrombin and factor Xa (2) .
In heparin, a specific local structure consisting of a pentasaccharide sequence with a specific sugar composition and sulfation pattern, is required to induce an activating conformational change in antithrombin (3, 4) . Heparin has an additional anticoagulant mechanism resulting from bridging the proteinase and the antithrombin molecules (5) . This last mechanism appears more significant for heparin acceleration when thrombin is the target proteinase. The conformational change is primarily responsible for heparin acceleration when factor Xa is the target proteinase because the synthesized pentasaccharide region is nearly as active as a full-length heparin containing this sequence.
Heparin has several side effects, such as development of thrombocytopenia (6, 7) , hemorrhagic effect (8, 9) , ineffectiveness in congenital or acquired antithrombin deficiencies, and incapacity to inhibit thrombin bound to fibrin (10) , among others. In addition, heparin is mostly extracted from pig intestine or bovine lung, where it occurs in low concentrations. Furthermore, the incidence of prion-related diseases in mammals and the increasing need for antithrombotic therapy indicate that we should look for alternative sources of anticoagulant and antithrombotic compounds.
One abundant source of new anticoagulant polysaccharides is marine algae. They contain a variety of sulfated galactans (11) (12) (13) and sulfated fucans (14 -17) . They are among the most abundant non-mammalian sulfated polysaccharides found in nature. Other sulfated polysaccharides with anticoagulant activity are found in marine invertebrates (18 -22) . These polysaccharides are potent thrombin and factor Xa inhibitors mediated by antithrombin or heparin cofactor II. Obviously, the specific pentasaccharide sequence required for heparin to induce the activating conformational change in antithrombin is absent in the algal and invertebrate polysaccharides. This raises the following interesting questions. How can these polysaccharides activate antithrombin? Do their structures mimic the specific pentasaccharide sequence found in heparin or is another mechanism involved in their ability to activate antithrombin?
In order to clarify these aspects, we undertook a systematic analysis of the anticoagulant activity of sulfated galactans obtained from marine organisms. The specific pattern of sulfation and the position of the glycosidic linkage vary among different species. The sea urchin Echinometra lucunter contains a linear polysaccharide composed of 2-sulfated, 1,3-linked ␣-L-galactose (Fig. 1B) (23) , whereas in the tunicate Herdmania monus a similar polysaccharide is composed of 3-sulfated, 1,4-linked ␣-L-galactose (Fig. 1C) (24) . The sea urchin Strongylocentrotus franciscanus contains a related polysaccharide composed of 2-sulfated, 1,3-linked ␣-L-fucose (Fig. 1D) (25) . Finally, the following repeating structure (-4-␣-D-Gal-133-␤-D-Gal-13) was found in the red alga Botryocladia occidentalis. One-third of the total ␣-units are 2,3-di-sulfated, and another one-third are 2-sulfated (Fig. 1A) . The potent anticoagulant activity of this algal galactan (potency similar to that of unfractionated heparin) was attributed mostly to the 2,3-di-sulfated units (13) .
We now report that the structural requirements for interaction of the sulfated galactans with coagulation inhibitors and their target proteinases are stereo-specific and not merely a consequence of their charge density or sulfate content. Sulfated galactans have a decreased antithrombin affinity and an inability to induce a full activation conformational change in the plasma inhibitor but can achieve an anticoagulant activity similar to that of heparin. Finally, heparin and sulfated galactans have different binding sites on antithrombin. Therefore, the paradigm of heparin-antithrombin interaction cannot always be extended to other sulfated polysaccharides.
EXPERIMENTAL PROCEDURES
Sulfated Polysaccharides-Sulfated galactans and sulfated fucan were extracted from the red alga B. occidentalis and from the invertebrates E. lucunter, H. monus, and S. franciscanus by protease digestion and purified by anion-exchange chromatography. The purity of each fraction was checked by agarose gel electrophoresis and NMR spectroscopy, as described (13, 23, 26) . Dermatan sulfate from bovine intestinal mucosa and chondroitin 6-sulfate from shark cartilage were from Sigma. Heparin was the fourth International Standard (85/502) and low molecular weight heparin (66 IU/mg) was the first International Standard (85/600), both from the National Institute for Biological Standards and Control (Potters Bar, UK).
Anticoagulant Action Measured by Activated Partial Thromboplastin Time-Activated partial thromboplastin time (APTT) 1 clotting assays were carried out by the method of Anderson et al. (27) using normal human plasma or antithrombin ϩ heparin cofactor II-depleted plasma obtained from Affinity Biologicals (Ontario, Canada). In these assays, plasma samples (90 l) were mixed with different amounts of sulfated polysaccharide in 0.9% NaCl (10 l) and warmed for 60 s at 37°C, and then 100 l of prewarmed APTT reagent (Celite-Biolab) was added and allowed to incubate for 2 min at 37°C. Prewarmed 0.25 M calcium chloride (100 l) was then added, and the APTT was recorded as the time for clot formation in a coagulometer (Amelung KC4A). The activity was expressed as international units/mg using a parallel standard curve based on the 4th International Heparin Standard (193 IU/mg).
Inhibition of Thrombin or Factor Xa by Antithrombin and Heparin Cofactor II in the Presence of Sulfated Polysaccharides-Incubations
were performed in disposable semi-microcuvettes. The final concentrations of reactants included 50 nM antithrombin or 68 nM heparin cofactor II, 15 nM thrombin, or factor Xa and 0 -1000 g/ml sulfated polysaccharide in 100 l of TS/PEG buffer (0.02 M Tris/HCl, 0.15 M NaCl, and 1.0 mg/ml polyethylene glycol, pH 7.4). Thrombin or factor Xa was added last to initiate the reaction. After 60 s of incubation at room temperature, 500 l of TS/PEG buffer containing 100 M chromogenic substrate S-2238 for thrombin or S-2222 for factor Xa (Chromogenix AB, Mondal, Sweden) was added, and the absorbance at 405 nm was recorded for 120 s. The rate of change of absorbance was proportional to the thrombin or factor Xa activity remaining in the incubation. No inhibition occurred in control experiments in which thrombin or factor Xa was incubated with antithrombin or heparin cofactor II in the absence of sulfated polysaccharide. In addition, no inhibition was observed when thrombin or factor Xa was incubated with sulfated polysaccharide alone over the range of concentrations tested.
Preparation and Analysis of Low Molecular Weight Fragments from the Sulfated Galactan of B. occidentalis-Sulfated galactan from B. occidentalis (40 mg) was dissolved in 1.0 ml of 0.1 M HCl, and the solution was incubated at 60°C for 60 min. Thereafter, the mixture was neutralized with 1.0 ml of 0.1 M NaOH. The partially hydrolyzed sulfated galactan was applied to a Sephacryl S-400/HR column (220 ϫ 0.75 cm), equilibrated with 0.2 M NH 4 HCO 3 , pH 7.0. The column was eluted with the same solution at a flow rate of 28 ml/h; fractions of 4 ml were collected and assayed by metachromasia using 1,9-dimethylmethylene blue (28) and by the phenol-H 2 SO 4 reaction (29) . The various fractions were pooled as four different subfractions, designated as F-I, F-II, F-III, and F-IV, and lyophilized.
PAGE-The molecular masses of the sulfated polysaccharides were estimated by PAGE (17, 19, 24) . In these experiments, the sulfated polysaccharides (ϳ10 g of each) were applied to a 6% 1-mm-thick polyacrylamide gel slab in 0.02 M sodium barbital, pH 8.6, and run for 30 min at 100 V. After electrophoresis the sulfated polysaccharides were stained with 0.1% toluidine blue in 1% acetic acid and then washed for about 4 h in 1% acetic acid. The molecular masses of the low molecular weight fragments from the sulfated galactan were determined by comparison with the electrophoretic mobility of standard compounds (17, 19, 24) .
1 H Nuclear Magnetic Resonance Spectra-1 H NMR spectra were recorded using a Bruker DRX 600 spectrometer with a triple resonance probe. About 3 mg of polysaccharide were dissolved in 0.5 ml of 99.9% D 2 O (Cambridge Isotope Laboratory). The spectra were recorded at 60°C with HOD suppression by presaturation. Chemical shifts are reported relative to external trimethylsilylpropionic acid at 0 ppm.
Antithrombin-Affinity Chromatography-An antithrombin affinity column was prepared as described by Höök et al. (30) . Briefly, 20 mg of antithrombin in 5 ml of coupling buffer (50 mM NaCl, 100 mM NaHCO 3 , pH 8.2) were mixed with 240 mg of N-acetylated heparin (120 mg/ml in 100 mM NaHCO 3 , pH 8.2) to block free amino groups in the glycosaminoglycan-binding sites of the antithrombin molecules. HiTrap NHSactivated HP (2 ml) from Amersham Bioscience was combined with the antithrombin/heparin solution, and coupling was carried out as described by the manufacturer. The immobilized antithrombin maintains full heparin binding activity, because it produces two distinct heparin fractions that differ markedly in their anticoagulant activities, estimated as 432 and ϳ20 IU/mg, respectively, based on the APTT assay. Intact sulfated galactans, their low molecular weight fragments, heparin from porcine intestinal mucosa, or chondroitin 6-sulfate from shark cartilage, both from Sigma (200 g of each), were applied to 1 ml of antithrombin affinity column, pre-equilibrated with 20 mM Tris/HCl, pH 7.4, and connected to an FPLC system from Amersham Biosciences. The column was washed with 10 ml of the same Tris solution and eluted at a flow rate of 0.5 ml/min by using a linear NaCl gradient of 0.15 3 3.0 M NaCl. Fractions of 0.5 ml were collected and analyzed for metachromatic property using 1,9-dimethylmethylene blue (28) . The NaCl concentration was estimated by conductivity, and the range of salt concentrations used in our experiments did not interfere with the metachromasy assay.
Modifications of Intrinsic Fluorescence of Antithrombin Induced by Sulfated Polysaccharide-Successive 2-l aliquots of 0.5 mg/ml stock solutions of heparin or sulfated galactans were added to 600 l of a 1 M solution of antithrombin in 0.01 M Tris/HCl, pH 7.5, containing 0.15 M NaCl. After 1 min, changes in the intrinsic fluorescence spectrum of antithrombin were monitored from 300 to 400 nm with excitation set at 280 nm, using an ISS/PC (Champaign, IL) spectrofluorimeter with a 1 ϫ 1 cm 2 quartz cuvette. The spectral areas were calculated according to the program provided by the equipment manufacturer. All experiments were performed at room temperature and under continuous stirring. Bandwidths were set at 0.5 nm for excitation and 2 nm for emission.
The dissociation constant (K d ) for the binding of heparin to antithrombin was calculated from the enhancing of tryptophan fluorescence emission. These data were analyzed by nonlinear regression binding Equation 1 (31) , Binding of Bis-ANS to Antithrombin-The binding of bis-ANS to antithrombin was monitored by the addition of increasing amounts of bis-ANS to a 1 M solution of antithrombin in 0.01 M Tris/HCl, pH 7.5, containing 0.15 M NaCl. After 1 min under continuous stirring, the fluorescence emission from bis-ANS was recorded between 400 and 600 nm by using an excitation wavelength of 360 nm. The extent of bis-ANS binding to antithrombin was evaluated using the spectral area.
Solutions of bis-ANS bound to antithrombin were titrated with sulfated galactan or heparin. For these experiments, 1 M antithrombin was incubated with 5 or 11 M bis-ANS for 3 h in 0.01 M Tris/HCl, pH 7.5, containing 0.15 M NaCl. This solution was then titrated with successive additions of 2 l of heparin or sulfated galactans (0.5-1.0 mg/ml). After 1 min under continuous stirring, intrinsic and extrinsic fluorescence was recorded, as described above.
Analysis of the Antithrombin-Thrombin Covalent Complex-The ability of sulfated polysaccharides to catalyze the formation of a covalent complex between antithrombin and thrombin was determined by incubation of 0.5 M human antithrombin and 1.4 M thrombin (both from Hematologic Technologies, Essex Junction, VT) in the absence or presence of heparin (0.01-1 g/ml) or sulfated galactans (1-100 g/ml) for 30 s at room temperature in TS/PEG buffer (final volume, 30 l). The reaction was stopped by addition of 15 l of electrophoresis sample buffer (40 mg/ml SDS, 20% (v/v) glycerol, and 0.125 M Tris/HCl, pH 6.8), followed by heating at 100°C for 5 min. An aliquot of the mixture (20 l) was subjected to electrophoresis (100 V for 1 h) on an SDS-10% PAGE (32). The gel was stained with 0.25% Coomassie Blue R-250 in 40% methanol and 10% acetic acid.
RESULTS

Anticoagulant Activity of Sulfated Galactans; Are There Specific Structural Motifs for the Anticoagulant Activity of Sulfated
Galactans?-The anticoagulant activity of sulfated fucan and galactans from different sources was evaluated by APTT assay (Table I ) and compared with that of heparin, a classical anticoagulant. The sulfated galactan from the red alga B. occidentalis (Fig. 1A) is the most potent among the galactans tested. This activity is greater than that of a linear sulfated ␣-Lgalactan from E. lucunter (20 IU/mg), composed solely of 2-sulfated, 1,3-linked units (Fig. 1B) . The galactan from H. monus (Fig. 1C) , which has its sulfation (3-sulfated) as well as its glycosidic linkage (1,4-linked) in different positions, presents no anticoagulant activity (ϳ2 IU/mg). The replacement of 2-sulfated ␣-L-galactose by 2-sulfated ␣-L-fucose in a polymer with the same glycosidic linkage (S. franciscanus, Fig. 1D ) does not restore the activity (ϳ2 IU/mg). These results indicate that the nature of the sugar residue and the sulfation position modify markedly the anticoagulant activity of these polysaccharides. The presence of 2,3-di-sulfated units in galactan molecules has an amplifying effect on the anticoagulant activity, so that the activity of B. occidentalis galactan is comparable with that of heparin (Table I ). This is not merely a consequence of an increased charge density because the anticoagulant activity increases ϳ6.5-fold between the sulfated galactan from E. lucunter and the sulfated galactan from B. occidentalis (based on APTT assays, Table I ), whereas the sulfate content increases only ϳ1.5-fold. Furthermore, the sulfated galactans from E. lucunter and H. monus have the same charge density (Fig. 1 , B and C) but differ by a factor of 10 in their anticoagulant activities (Table I) .
The sulfated galactans from B. occidentalis and E. lucunter lose their anticoagulant effects when they are tested in a clotting assay by using antithrombin-and heparin cofactor IIdepleted plasma (Table II) . This observation shows that their activities are dependent on the presence of these two cofactors. Furthermore, the sulfated galactans from B. occidentalis and E. lucunter enhance thrombin or factor Xa inhibition by antithrombin or heparin cofactor II with sigmoid curves similar to those observed for heparin or dermatan sulfate (Fig. 2) . The IC 50 for thrombin or factor Xa inhibition can be determined easily from these curves and is reported in Table I . Among all the galactans investigated, the IC 50 of that from B. occidentalis is closest to that of heparin and is significantly lower than that of dermatan sulfate, as expected based on the APTT assays. 2 For the sulfated galactan from E. lucunter, higher concentrations are required to obtain the same effect as with heparin or B. occidentalis galactan. With the other invertebrate polysaccharides, the thrombin activity based on antithrombin and heparin cofactor II inhibition is only marginally inhibited (Fig.  2 , A and C), even at much higher concentrations. For the sulfated galactan from H. monus, we observes a slight decrease of the inhibitory effect on thrombin mediated by antithrombin at higher polysaccharide concentrations ( Fig. 2A) . 3 In the case of factor Xa inhibition mediated by antithrombin, the effects of 2 The second-order rate constants (M Ϫ1 s Ϫ1 ) for thrombin inhibition in the presence of antithrombin as a function of sulfated galactan concentration were determined as described by Olson et al. (31) . The value for this constant in the absence of sulfated polysaccharide is 1. in the presence of 1, 10, 100, and 500 g/ml of B. occidentalis galactan, respectively. In three different experiments no decrease in the rate is observed up to the highest concentration of sulfated galactan tested (500 g/ml). The absence of a bell-shaped curve does not favor a bridging mechanism for thrombin inhibition, and thus differs from heparin (5). 3 Differences in anticoagulant activity observed among the sulfated polysaccharides cannot be ascribed to variation in the size of their chains. The various polysaccharides used in the experiments of Table I have similar molecular masses of ϳ100 kDa, as determined by PAGE and gel filtration chromatography on a Superose-6 (HR 10/30) column linked to an FPLC system. S. franciscanus and H. monus galactans are more pronounced (Fig. 2B) , although the curves are markedly displaced to higher polysaccharide concentrations.
In the experiment of Fig. 3 we tested whether the concentration of antithrombin limits the thrombin inhibition promoted by sulfated galactan. Both heparin and the sulfated galactan from B. occidentalis show almost coincident curves. Clearly, the concentration of antithrombin employed in the experiment of Fig. 2 (50 nM) ensures formation of an effective inhibitory complex between the polysaccharides and the plasma cofactor.
Overall, these results indicate that the anticoagulant activity of sulfated galactans is not merely a consequence of their charge density and sulfate content; instead, the structural requirements for interaction of these polysaccharides with coagulation cofactors and their target proteases are stereo-specific. The presence of 2,3-di-sulfated ␣-galactose units (e.g. for B. occidentalis) has an amplifying effect on the anticoagulant activity. Taken together, the data presented in Fig. 2 indicate the following order of inhibition of thrombin activity mediated by the two cofactors tested: heparin Ն B. occidentalis Ͼ Ͼ E. lucunter Ͼ Ͼ H. monus ϭ S. franciscanus.
Anticoagulant Activity of Sulfated Galactans: Does the Molecular Size Influence the Anticoagulant Activity of Sulfated
Galactans?-In order to investigate the role of molecular size in the anticoagulant activity of sulfated galactans, mild acid hydrolysis was performed to decrease the size of the B. occidentalis galactan. The fragments thus produced were separated by gel filtration on a Sephacryl S-400 column, where a wide dispersion of species with different molecular masses was observed (Fig. 4A) . The fractions were pooled into four different subfractions (F-I 3 F-IV) (Fig. 4A) . PAGE (Fig. 4B) confirmed that the molecular mass decreases from subfraction F-I to F-IV and that all subfractions possess a reduced molecular size when compared with the intact, sulfated galactan. Subfractions F-III and F-IV have approximately the same molecular mass as unfractionated heparin and low molecular weight heparin standards, respectively ( Fig. 4B and Table II) .
1 H NMR spectroscopy showed that the four subfractions have the same chemical structure because they have similar spectra (Fig. 5) . Like the native sulfated galactan, the subfractions present very complex 1 H NMR spectra, due to a heterogeneous sulfation pattern. Nevertheless, the observed signals can be clearly assigned to specific structures, as described in a previous study (13) . Thus, the signals at ϳ5.7 and 5.4 to 5.2 ppm are attributed to anomeric protons of 2,3-di-sulfated ␣-galactose units and 2-or non-sulfated units, respectively. Clearly, the 1 H NMR spectra confirm that the sulfation pattern of the algal galactan was not disrupted in the course of the mild acid hydrolysis. No marked difference is observed between the integrals of the anomeric signals in the native and low molecular weight sulfated galactans. In particular, the 2,3-di-sulfated ␣-galactose units, which we believe constitute the structural The column was eluted with the same solution at a flow rate of 28 ml/h; fractions of 4 ml were collected and assayed by metachromasia (q and f) and the Dubois et al. reaction (E). The ratio between the metachromatic reaction and the Dubois reaction decreases from the high to the low molecular weight subfractions, possibly due to the reduction in molecular size. The hydrolyzed galactan fractions were pooled into four subfractions, as indicated by the horizontal bars in A. B, intact sulfated galactan, the four low molecular weight subfractions, unfractionated and low molecular weight (LMWH) heparins (ϳ10 g of each), were applied to a 6% 1-mm-thick polyacrylamide gel slab in 0.02 M sodium barbital (pH 8.6) and run for 30 min at 100 V. After electrophoresis, the sulfated polysaccharides were stained with 0.1% toluidine blue in 1% acetic acid and then washed for about 4 h in 1% acetic acid. The molecular masses of the low molecular weight fragments from the sulfated galactan were determined by comparison with the electrophoretic mobility of standard compounds, indicated at the right.
motif that confers a high anticoagulant activity on the intact sulfated galactan from B. occidentalis, are still present in the low molecular weight fragments.
The anticoagulant activities based on APTT assays with the fragments obtained from B. occidentalis galactan are listed in Table III . The activity decreases sharply on going from the high molecular weight subfraction F-I to the low molecular weight subfraction F-IV, which has no activity. Most interesting, although subfractions F-III and F-IV are equivalent in size to the unfractionated heparin and the low molecular weight heparin, respectively, their activities are much lower. These results suggest that the sulfated galactans require chains with significantly greater length compared with heparin in order to achieve their function as anticoagulants.
The experiments based on amidolytic activity ( Fig. 6 ; see also the IC 50 values in Table III ) permit a more refined comparison among the activities of the low molecular weight sulfated galactans. Inhibition of thrombin activity in the presence of antithrombin is markedly reduced with the decrease in molecular size of the polysaccharide (Fig. 6A) . Total inhibition of thrombin is not achieved in dose-effect curves with subfragments F-I (ϳ45 kDa), F-II (ϳ30 kDa), or F-III (ϳ15 kDa); about ϳ50% of thrombin activity remains. The activity is totally abolished for fragments of ϳ5 kDa or less. Curiously, a high concentration of subfraction F-III causes a decrease in its inhibition of thrombin activity, as already observed for the sulfated galactan from H. monus ( Fig. 2A) .
When we use factor Xa instead of thrombin as the target protease (Fig. 6B) , total inhibition of the protease is observed for all subfractions of the sulfated galactans with molecular sizes down to ϳ15 kDa (F-I-F-III), although all curves are displaced to the right in relation to the effect of the intact polysaccharide. Again, subfraction F-IV has no effect.
In a similar fashion, if we replace antithrombin by heparin cofactor II as the target plasma inhibitor, the low molecular weight sulfated galactans F-I to F-III retain the sigmoid curves and achieve total thrombin inhibition, whereas F-IV is inactive. Surprisingly, subfractions F-I and F-II are even more active than the intact polysaccharide (Fig. 6C, open circles) . A possible explanation for this potentiation in the inhibitory effects of F-I and F-II is that the solutions containing these low molecular weight polysaccharides are more concentrated on a molar basis than the solution containing the intact chain.
Overall, our results indicate that the molecular size modifies markedly the anticoagulant activity of sulfated galactan, with variable effect depending on the target protease or plasma inhibitor employed in the assays. In the case of B. occidentalis galactan, the activity is retained in fragments ranging in size down to ϳ15 kDa for thrombin or factor Xa inhibition mediated by heparin cofactor II or antithrombin, respectively. In contrast, total thrombin inhibition in the presence of antithrombin requires fragments with much higher molecular size (Ͼ45 kDa).
Formation of Sulfated Galactan-Antithrombin Complex; Does the Sulfated Galactan Interact with Antithrombin in the Same Way as
Heparin?-A variety of methods has been employed to trace the formation of the heparin-antithrombin complex (30, (33) (34) (35) (36) (37) . Fig. 7A shows the elution of heparin from an antithrombin column. As seen, there are two populations of heparin, one that is retained (eluting at ϳ28 min) and another one that is not retained (eluting at ϳ12 min) in the column. The latter population corresponds to molecules of heparin devoid of the pentasaccharide sequence, which ensures high affinity for antithrombin (3, 4) . 4 The non-coagulant chondroitin 6-sulfate is not retained on the column.
The elution profiles of sulfated galactans from E. lucunter (Fig. 7B) and B. occidentalis (Fig. 7C) show only a single population that is retained in the column. On the other hand, the fragments obtained by acid hydrolysis of the sulfated galactan from B. occidentalis present a heterogeneous behavior. Like the intact polysaccharide, subfraction F-II is retained on the antithrombin affinity column (Fig. 7D) . In contrast, only part of subfraction F-III is retained, and subfraction F-IV does not bind at all to the affinity column.
The molecular sizes of the polysaccharides obtained from the antithrombin affinity column were determined by PAGE (Fig.  7E) . Clearly, binding of the sulfated galactan to the antithrombin column depends on the molecular size. This is especially noteworthy for subfraction F-III, because the retained and non-retained populations clearly differ in size (Fig. 7E) .
The experiments of Fig. 7 suggest that the bulk structure of the sulfated galactan determines the interaction with antithrombin. If a specific minor component were important for this interaction (as is the pentasaccharide sequence in heparin), we would expect a partial retention of sulfated galactans in the affinity column without a clear molecular size dependence, as found for heparin. Of course we cannot totally exclude that the decreased activity observed with the low molecular weight subfractions may reflect loss of a rare and possibly lengthy structural motif of the polysaccharide chain. The long polysaccharide chain of the native sulfated galactan may bind the immobilized antithrombin in a multivalent interaction. However, this type of linkage would not be expected to occur with the low molecular weight subfractions, especially that of F-III, which is retained in the affinity column and has a molecular size similar to heparin. 
Do Heparin and the Sulfated Galactans Bind to the Same
Site on Antithrombin?-Because the sulfated galactan apparently binds to antithrombin in a molecular size-dependent fashion, the next question we addressed concerns the possibility of a single, unspecific polysaccharide-binding site on antithrombin that can bind either heparin or the sulfated galactans. In order to clarify this point, we followed the changes in the intrinsic and extrinsic fluorescence of antithrombin as it binds sulfated galactan and compared them to changes induced by heparin binding. As reported previously (33) (34) (35) , the addition of increasing concentrations of heparin to an antithrombin solution induces a progressive increase of ϳ30% in its tryptophan fluorescence emission (Fig. 8) . 5 This methodology has been widely used to follow the antithrombin conformational change induced by heparin binding (33) (34) (35) . Surprisingly, neither the sulfated galactan from E. lucunter nor that from B. occidentalis, which has an anticoagulant activity similar to heparin (Table I) , was able to modify the intrinsic fluorescence of antithrombin (Fig. 8) . The fragment derived from B. occidentalis galactan (subfraction F-III, Table III) , which has a molecular weight similar to unfractionated heparin, gave an identical result (not shown). The difference in response of the antithrombin tryptophan residues to heparin or sulfated galactan binding suggests the existence of two different binding sites on the protein.
Another possible explanation for the lack of change in intrinsic fluorescence intensity upon galactan binding (Fig. 8) is that under the conditions used to follow antithrombin fluorescence, sulfated galactan does not interact with the protein and therefore does not modify the tryptophan emission. In order to clarify this point, we removed a sample of the sulfated galactanantithrombin solution at the end of the fluorescence assay and tested its activity on thrombin using a chromogenic substrate (assay similar to that used in Fig. 2A ). The potent inhibitory activity of B. occidentalis galactan-antithrombin solution obtained from the same sample used for the fluorescence assay (similar to that of the unprocessed polysaccharide shown in Fig. 2A) demonstrates that the sulfated galactan forms an active complex with antithrombin under these conditions.
In order to confirm that indeed the sulfated galactans bind to a different site on antithrombin, we took advantage of bis-ANS, a hydrophobic probe that has been used to map intermediate states in the folding pathway of several proteins (39) . Bis-ANS is suitable for these measurements because when free in solution its a The average molecular masses of the sulfated polysaccharides were determined by PAGE (Fig. 4B) . b The activity is expressed as international units/mg using a parallel standard curve based on the International Heparin Standard (193 units/mg). Data are shown as mean Ϯ S.D., n ϭ 4.
c Data are shown as mean Ϯ S.D., n ϭ 3. d These subfractions were obtained by partial acid hydrolysis with 0.1 M HCl at 60°C for 60 min, followed by separation of the fragments on a Sephacryl S-400 column (Fig. 4) .
e International standard. f ND, not determined antithrombin (A and B) or heparin cofactor II (C). The experiments were as described in the legend of Fig. 2 . For comparison the curves obtained in Fig. 2 with standard heparin and dermatan sulfate are also shown (broken lines). The panels show a typical result representative of three different experiments.
fluorescence emission is negligible (see Fig. 9C ), whereas upon its binding to apolar and positively charged pockets on proteins its fluorescence emission increases enormously (40, 41) .
The fluorescence of bis-ANS in the presence of native antithrombin is very prominent (see Fig. 9C ), which suggests that the probe is bound to the protein. Possibly it binds at the heparin-binding site, because bis-ANS has sulfonic acid groups. The addition of increasing concentrations of bis-ANS to 1 M antithrombin solution leads to a progressive increase in bis-ANS emission that levels off at 11 M (Fig. 9, A and C) . In parallel, tryptophan emission decreases due to the quenching effect exerted by bis-ANS on tryptophan emission (Fig. 9, A and  B) . This suggests that the binding site of bis-ANS is close to the tryptophan(s) of antithrombin that makes the major contribution to its intrinsic fluorescence. Antithrombin has four tryptophan residues. A study using four variants of antithrombin containing single Trp 3 Phe mutations indicated that Trp-225 and Trp-307 are the most responsive to heparin binding (42) , and thus these two residues are likely targets.
To investigate whether bis-ANS competes with heparin at the same binding site on antithrombin, we titrated a solution of antithrombin previously incubated in the presence of 5 M bis-ANS (Fig. 10) . As seen, there is a progressive decrease in bis-ANS emission when heparin binds to antithrombin (Fig.   10A, circles) , suggesting that the polysaccharide displaces the probe from the same binding site. In parallel, as heparin binds to antithrombin, the tryptophan emission that was quenched by bis-ANS is released, increasing in magnitude (Fig. 10B,  circles) . When 60 g/ml heparin was added to the antithrombin solution as in Fig. 10A , a spectral area ratio of 0.33 Ϯ 0.14 (n ϭ 4) was observed. This indicates that not all bis-ANS was removed from the protein, even at a high heparin concentration. Furthermore, not all tryptophan emission was recovered by heparin addition. Thus, addition of 5 M bis-ANS to 1 M antithrombin solution quenched 76 Ϯ 3% (n ϭ 3) of the tryptophan emission, whereas only 52 Ϯ 3% of its original emission is recovered by the addition of 60 g/ml heparin.
Next, we investigated whether the sulfated galactans can also displace bis-ANS from the protein domain. As seen in Fig.  10 , the sulfated galactans can displace bis-ANS from its binding site on antithrombin (Fig. 10A, squares) , but not to the same extent as heparin does. In this regard, the sulfated galactan from B. occidentalis is more effective than the galactan from E. lucunter, in accordance with its more effective action as an inhibitor of thrombin activity (Table I ). The same data are obtained with a higher concentration of bis-ANS (11 M) (not shown). As expected from Fig. 8 , the tryptophan emission of antithrombin is not enhanced as the sulfated galactans bind FIG. 7 . Antithrombin affinity chromatography of intact and low molecular weight sulfated galactans. Heparin from porcine intestinal mucosa and chondroitin 6-sulfate from shark cartilage (CS) (both from Sigma) (A), intact sulfated galactan from E. lucunter (B) or B. occidentalis (C) and its low molecular weight fragments (D) (200 g of each) were applied to an antithrombin affinity column (HiTrap NHS-activated 1 ml, coupled with 10 mg antithrombin), connected to an FPLC system. The column was eluted with a linear gradient of 0.15 3 3.0 M NaCl at a flow rate of 0.5 ml/min. The fractions were checked for their metachromatic properties, and the NaCl concentration (---) was estimated by conductivity. Fractions obtained from the low molecular weight fragments of sulfated galactans (D) were pooled, dialyzed against distilled water, and lyophilized. E, the retained and non-retained fractions of low molecular weight sulfated galactans (10 g of each) were run on a 6% polyacrylamide gel, as described in the legend of Fig. 4 . UFH, unfractionated heparin; LMWH, low molecular weight heparin.
( Fig. 10B, squares) . Taken together, these data suggest the existence of two different polysaccharide-binding sites on antithrombin, which may share common features such as positive charges that allow bis-ANS binding.
Does the Sulfated Galactan Catalyze the Formation of a Covalent Complex between Antithrombin and
Thrombin?-Antithrombin forms a covalent complex with thrombin in a process that is catalyzed by heparin. This complex is easily detected on SDS-PAGE (37). In Fig. 11 , we use this methodology to show that the sulfated galactans from B. occidentalis and E. lucunter induce the formation of a covalently linked complex between antithrombin and thrombin with the same molecular mass as that obtained in the presence of heparin. 6 However, the concentrations of the sulfated galactans required to catalyze the same extent of formation of antithrombin-thrombin complex are much higher than that of heparin. At ϳ0.1 g/ml heparin already induces maximum incorporation of antithrombin into the covalent complex (Fig. 11A) , whereas only 100 g/ml of the sulfated galactan from B. occidentalis promotes the same incorporation (Fig. 11B, right lane) . The polysaccharide from E. lucunter, even at 100 g/ml, is unable to induce maximum complex formation.
DISCUSSION
Our results clearly allow two major conclusions. 1) The activating conformational change in antithrombin is less important for the anticoagulant activity of sulfated galactan than for heparin.
2) The antithrombin-sulfated galactan complex differs from the antithrombin-heparin complex. Although we are not yet prepared to propose a new mechanism for antithrombin-dependent thrombin inhibition by sulfated galactan, our results show that the paradigm of the heparin-antithrombin interaction cannot necessarily be extended to other sulfated polysaccharides. Each type of polysaccharide may form a particular fluorescence was recorded by using emission spectra from 300 to 400 nm for tryptophan (excitation at 280 nm) and from 400 to 600 nm for bis-ANS (excitation at 360 nm). B and C show typical spectra in the absence (free AT) and in the presence of 5 and 11 M bis-ANS, showing that tryptophan emission is quenched by the addition of bis-ANS (B), whereas bis-ANS emission increases due to the bound probe (C).
complex with the coagulation inhibitor and the target protease.
Sulfated Galactans as Anticoagulants; the Activating Conformational Change in Antithrombin Is Less Important-This study describes the structural requirements for interaction of sulfated galactans with coagulation cofactors and their target serine proteases. We show that linear sulfated galactans express anticoagulant activity not merely as a function of charge density. The structural basis of this interaction is complex because it involves naturally heterogeneous polysaccharides, but certainly it depends on the monosaccharide composition, sites of sulfation and/or of the glycosidic linkage, and the occurrence of disulfated units.
A slight decrease in the molecular size of the sulfated galactan dramatically reduces its effect on thrombin in the presence of antithrombin. Even when we replace thrombin by factor Xa, the sulfated galactan always requires fragments with much higher molecular masses than that of heparin to inactivate the protease. Sulfated galactan with an average molecular size from ϳ45 to ϳ15 kDa binds to antithrombin but is unable to bridge the plasma inhibitor and thrombin. For this last effect a molecular size above ϳ45 kDa is required.
Heparin can be separated on an antithrombin affinity column into low affinity and high affinity fractions. The occurrence of a specific pentasaccharide sequence in the heparin chain plays an important role in mediating the binding of heparin to antithrombin and its ability to induce a full activating conformational change in the plasma inhibitor (3, 44, 45) . However, low affinity heparin, which is not retained on the affinity column and is devoid of the specific pentasaccharide sequence (5), also has anticoagulant activity, albeit with a reduced magnitude. Its reduced effectiveness is attributed to a decreased antithrombin affinity and to its inability to induce a full activating conformational change in the plasma inhibitor (5) . This effect of the low affinity heparin on antithrombinmediated thrombin inhibition has been denominated the "bridging effect" in contrast with the "activating conformational change mechanism" reported for high affinity heparin (5).
Our observations with the sulfated galactans suggest an antithrombin-mediated thrombin inhibition that differs from the one reported for high and low affinity heparins. Sulfated galactans (like high affinity heparin) are retained on an antithrombin affinity column (Fig. 7 , B and C) but (like low affinity heparin) have a markedly reduced ability to induce an activating conformational change in antithrombin. This is supported by the observation that when the sulfated galactans are added to an antithrombin solution, they do not induce an increase in intrinsic fluorescence, as observed for heparin (Fig. 8) . Furthermore, although the dissociation constants for the binding of B. occidentalis galactan and heparin to antithrombin differ significantly (as determined by the titration curves of Fig. 10A ), both polysaccharides enhance thrombin inhibition by antithrombin in the same range of concentration on a weight basis ( Figs. 2A and 3) . Thus, two questions arise. Do these two polysaccharides form a covalent complex with antithrombin with equal efficiency? Does the inhibition operate by a similar mechanism? Certainly they differ markedly in their ability to induce the formation of covalent complex between thrombin and antithrombin, as indicated by the experiments of Fig. 11 . Heparin induces almost total incorporation of antithrombin into the covalent complex at a concentration of ϳ0.1 g/ml (Fig.  11A) . In contrast, B. occidentalis galactan, with approximately the same anticoagulant potency as heparin (Table I) , requires a significantly higher concentration (ϳ100 g/ml) in order to achieve the same effect (Fig. 11B ). These observations indicate that the sulfated galactan from B. occidentalis can achieve activity similar to heparin but at a significantly lower concentration of the covalent complex between antithrombin and thrombin.
We may speculate about several possible mechanisms for the potent action of sulfated galactan on antithrombin-mediated thrombin inactivation. The polysaccharide may hold together more than one molecule of the protease and/or of the plasma cofactor in a non-covalent complex. Alternatively, the sulfated galactan may promote the antithrombin-thrombin reaction via the same bridging effect proposed for low affinity heparin (5) . In this case its efficacy can be attributed to the longer chains that occur in the sulfated galactan. We cannot exclude that an initial non-covalent complex is formed between the polysaccharide and thrombin, which increases the affinity of the sulfated galactan for antithrombin. All these possibilities require further investigation. Fig. 12 we present a model that summarizes our data related to the polysaccharide-binding sites on antithrombin. We propose that heparin and the sulfated galactans have different binding sites on antithrombin based on fluorescence studies. At least two of the tryptophan residues that contribute to antithrombin emission are located close to the heparin-binding site (42) . The emission of these residues responds to heparin binding by an increase in signal of ϳ30%. The heparin and the sulfated galactan-binding sites on antithrombin also bind bis-ANS because the polysaccharides and bis-ANS share similar properties such as negative charges due to the presence of sulfates. Bis-ANS competes for the heparin-and sulfated galactan-binding sites, but with different affinities (heparin Ͼ Ͼ sulfated galactan). When bis-ANS binds to antithrombin, tryptophan emission is quenched due to its proximity to the heparin-binding site. The addition of heparin displaces bis-ANS from the heparin-binding site restoring tryptophan emission. The same does not hold for the sulfated galactans. Thus, just by following the increase in tryptophan emission that takes place when heparin binds but does not take place when sulfated galactans bind, we could not argue for the existence of two different polysaccharide-binding sites on antithrombin. The differences in the spectroscopic behavior of tryptophan may indicate that a conformational change takes place upon heparin binding but not upon sulfated galactan binding. The use of bis-ANS provides clearer evidence for the presence of two different binding sites on antithrombin, because the sulfated galactan binding caused bis-ANS release (decrease of its fluorescence signal) without any change in the emission of the tryptophan residues that are close to the heparin-binding site.
Antithrombin-sulfated Galactan Complex Differs from Antithrombin-Heparin Complex-In
Possibly, antithrombin has additional sites for bis-ANS, which are not displaced by the sulfated polysaccharides. Approximately 33% of the bis-ANS signal persists even at a high heparin concentration, indicating only partial displacement of bound bis-ANS. Furthermore, not all of the original tryptophan emission was recovered by heparin titration.
Our results concerning the antithrombin-mediated anticoagulant activity of sulfated galactans may help to design new drugs with specific actions on coagulation and thrombosis. For example, these new sulfated polysaccharides may be active in patients with inherited antithrombin deficiency due to a mutation in the heparin-binding site (46 -48) . FIG. 12 . Proposed mechanism for the binding of bis-ANS and sulfated polysaccharides to antithrombin. We propose that heparin and the sulfated galactan have different binding sites on antithrombin. A, free antithrombin; the large rectangle represents antithrombin. The two small rectangles with positive changes represent the binding sites for heparin and sulfated galactan. The tryptophans that contribute to antithrombin intrinsic fluorescence emission are represented as empty circles. Antithrombin has additional binding sites for bis-ANS, here represented as a line with positive charges. B, bis-ANS binding to antithrombin; bis-ANS is represented by black circles. When bis-ANS binds to available positively charged sites on antithrombin, tryptophan emission is quenched. C, binding of heparin and sulfated galactan to bis-ANS-bound antithrombin. Left, heparin addition displaces bis-ANS from the heparin-binding site leading to a decrease in its fluorescence emission with a concomitant increase in tryptophan emission. Right, addition of sulfated galactan also leads to bis-ANS release although with no change in tryptophan emission. Note that the additional bis-ANS-binding site on antithrombin and its tryptophan residues remain unaffected by either heparin or sulfated galactan binding.
